ImmuCell Corporation (ICCC)vsRevolution Medicines Inc (RVMD)
ICCC
ImmuCell Corporation
$9.61
-2.63%
HEALTHCARE · Cap: $86.94M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
ImmuCell Corporation generates 3934% more annual revenue ($29.93M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -1.8%. ICCC earns a higher WallStSmart Score of 44/100 (D).
ICCC
Hold44
out of 100
Grade: D
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$17.77
Current Price
$9.61
$8.16 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 28.4% year-over-year
Earnings expanding 31.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -1.9% — below average capital efficiency
Currently unprofitable
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ICCC profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ICCC is growing revenue faster at 28.4% — sustainability is the question.
ICCC generates stronger free cash flow (3M), providing more financial flexibility.
Bottom Line
ICCC scores higher overall (44/100 vs 24/100) and 28.4% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?